Skip to content
Screener

Ultragenyx Pharmaceutical RARE Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$166.5MBeat by $547.9K
EPS-$1.17Beat by $0.10
Revenue estimate$165.9M
EPS estimate-$1.27

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$182.9M
EPS estimate-$0.65

Financials

Q2 2025

Income statement

See full
Revenue$167.0M+13.6%
Operating income-$108.0M+7.2%
Net income-$115.0M+12.6%
EPS (diluted)-$1.17+23.0%

Balance sheet

See full
Cash & equivalents$176.0M-63.4%
Total debt$36.3M—
Total equity$151.0M-65.1%
Total assets$1.3B-19.3%

Cash flow

See full
Operating cash flow-$109.0M-41.6%
CapEx$3.0M+49.3%
Free cash flow-$112.0M-41.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$3.51B+1.4%
Enterprise value$3.37B—
P/S5.8×-1.4×

Profitability

See full
Operating margin-82.8%-17.8pp
Net margin-87.3%-19.2pp
FCF margin-70%-16.1pp

Returns & leverage

See full
Return on equity-182.6%-20.2pp
Debt / equity0.2×—
Current ratio2.5×-1.1×

Segments

By geography

See full
North America$103.0M+15.9%
Latin America$33.0M-15.2%
EMEA$27.0M+67.1%
Asia Pacific$4.0M+31.1%

By product

See full
Collaboration And Royalty$121.0M+6.4%
Royalty$86.0M+17.5%
Non Cash Royalty$31.0M+17.9%

FAQ

When did Ultragenyx Pharmaceutical report Q2 2025 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Ultragenyx Pharmaceutical's Q2 2025 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $166.5M and eps of $-1.17 for Q2 2025.
Did Ultragenyx Pharmaceutical beat estimates in Q2 2025?
Revenue beat the consensus estimate of $165.9M by $547.9K. EPS beat the consensus estimate of $-1.27 by $0.10.
How did Ultragenyx Pharmaceutical's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.2% from $147.0M a year earlier and eps grew 23.0% from $-1.52.
Where can I find Ultragenyx Pharmaceutical's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-103026) and the 10-Q periodic report (0000950170-25-103290) directly on SEC EDGAR. The filing index links above go to sec.gov.